Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.

A survey of patients with advanced cancer treated by biologic response modifiers (BRMs), including (i) recombinant interleukin-2 and lymphokine-activated killer cells, (ii) recombinant interleukin-2 and alpha interferon, and (iii) tumor necrosis factor, was done. A total of 52 patients were reviewed...

Olles dieđut

Bibliográfalaš dieđut

Publikašuvnnas:	J Clin Microbiol
Váldodahkkit:	Maoleekoonpairoj, S, Mittelman, A, Savona, S, Ahmed, T, Puccio, C, Gafney, E, Skelos, A, Arnold, P, Coombe, N, Baskind, P
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	American Society for Microbiology (ASM) 1989
Fáttát:	Research Article
Liŋkkat:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC267014/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2584381/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jcm.27.10.2305-2308.1989
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!